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Abstract
The Japanese pharmaceutical industry has been growing steadily
since the 1970's. The early success, however, largely depended on
technological "diffusion" including technology transfer or licensing
of competitive foreign pharmaceutical products followed by
development of incremental drugs which largely contributed to the
early prosperity of domestic industry. Recently, transformation in
distribution of major causes of death and emerging new types of
diseases have been affecting the shift of the Japanese Government
health care policies. Do the current Japanese health care policies
promote innovative research and development in the Japanese
pharmaceutical industry? Do the policies demarcate radical
research and development from incremental one? This paper
explores the influence of health care policies on innovative R&D in
the Japanese pharmaceutical industry by answering two questions
above. In such a strongly regulated industry, the effect of
government policies on the decision of industry's future policies
would be substantial.
First, the present situation of The Japanese pharmaceutical industry
is analyzed in terms of scopes, significances, and trends. Then, I
investigates regulatory factors in health care policies which
influence innovative R&D to identify significant barriers. Finally, I
conclude the tendency and future of the health care policies for
innovative R&D based on the analysis.
Thesis Supervisor: Dr.Stan N. Finkelstein, M.D.
Title: Executive Director, Program on the Pharmaceutical Industry
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1. Introduction
The Japanese pharmaceutical industry has been growing steadily
since the 1970's. The early success, however, largely depended on
technological "diffusion" including technology transfer or licensing
of competitive foreign pharmaceutical products followed by
development of incremental drugs which largely contributed to the
early prosperity of domestic industry. Recently, transformation in
distribution of major causes of death and emerging new types of
diseases have been affecting the shift of the Japanese Government
health care policies. Do the current Japanese health care policies
promote innovative research and development in the Japanese
pharmaceutical industry? Do the policies demarcate radical
research and development from incremental one? This paper
explores the influence of health care policies on innovative R&D in
the Japanese pharmaceutical industry by answering two questions
above. In such a strongly regulated industry, the effect of
government policies on the decision of industry's future policies
would be substantial.
This paper does not argue either whether promoting innovative
R&D is good or harm nor which is better, radical R&D or incremental
one.
Because innovative R&D brings the expected technological
superiority and the contribution to global technological fields, but
still presents the possibility of undermining the industry because of
its capital-intensive nature. Incremental R&D can alleviate risk and
cost of R&D and is a one of the conventional ways to develop radical
drugs ultimately.
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2. Methodology of analysis
This analysis is based on government reports, related articles,
books, and field interviews. In Chapter 3, I analyze the present
situation of The Japanese pharmaceutical industry to identify
scopes, significances, and trends. In Chapter 4, regulatory factors in
health care policies which influence innovative R&D are
investigated. Finally, I conclude the tendency and future of the
health care policies for innovative R&D based on the analysis.
The definition of term, "innovation", is the following.
Technological "innovation", by definition, the first commercially
successful application of a new technological idea including radical
shifts or incremental ones in technology. Innovation should be
distinguished from "invention", which is the development of a new
technological ides, and from "diffusion", which is the subsequent
widespread adaptation of an innovation by those who did not
develop it. The distinction between "innovation" and "diffusion" is
complicated by the fact that innovations can rarely be adopted by
new users without modification. When modification are extensive,
the result may be a new innovation. 1
1Ashford, Nicolas A., " A United Technology-Based Strategy for Incorporating
Concern about Risks, Costs, and Equity in Setting National Environmental
Priorities," November 1992, p.2 .
This definition draw on a history of several years' work at the Center for
Policy Alternatives at the Massachusetts Institute of Technology, beginning
with a five-country study: "National Support for Science and Technology: An
Explanation of the Foreign Experience."
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3. Current situation of the Japanese pharmaceutical
industry
3.1 Demand for innovative drugs
These days, demand for innovative drugs is increasing. The
following demand mainly contribute to give a big incentive to
pharmaceutical firms to promote innovative R&D.
(1) Market demand
The most significant component of the demand for innovative drugs
is the demand of the market. In the past 30 years, causes of death
in industrialized countries have drastically shifted from infectious
diseases toward chronic diseases. In Japan, cancer, cerebral disease,
and cardiovascular disease record the three highest mortality rates.
(see Figure 1) The aging society has also contributed to those
epidemiologic changes. Japan's elderly reached 11% of population in
1987.
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Figurel: Death Rate by Major Causes
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Recently, new types of diseases also have emerged: Acquired
Immune Deficiency Syndrome (AIDS); Adult T-cell Leukemia (ATL);
hepatitis B; senile dementia; etc. The former three are the
untraceable viruses and bear high mortality rates. AIDS became
epidemic in the early 1980s and has spread rapidly through sexual
intercourse or the use of contaminated drug apparatus. ATL, an
endemic disease, is especially prevalent in Japan and results in
break down of the immune system by cancerous T-cell. Reportedly,
95% of patients die within 2 years after falling ill. In Japan,
approximately 80% of patients with hepatitis are suffering from
9
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hepatitis B which can cause permanent damage to liver tissue,
resulting in hepatic coma and death. Pharmaceutical companies are
aiming at catching these market demand in time to expand profits
and sales volume.
(2) Demand of the Government
The Second factor is the government demand. The Japanese
Government continues to make efforts to improve the health care
standards of its people by promoting the nation's health. The
government's main objective is to provide high-quality medical
practices including prevention and treatment. To achieve this end,
the government tries to response unexpected diseases or
devastating diseases as quick as possible.
(3) Emerging technology
Thirdly, emerging technologies such as biotechnology, new
materials, etc., have provided great impetus for innovative R&D.
Genetic engineering has already been applied to antibiotics,
enzymes, antibodies, hormones, vaccines, etc., and has improved the
speed, efficacy, and productivity of innovative R&D. By using
biotechnology's versatility, several companies in other industries
such as chemical, food processing, and molecular electronics, are
developing innovative drugs. (ex. Kirin, Ashahi, Sapporo, Ajinomoto,
Meiji, Tejin, etc.) Although these industries' distribution systems of
drugs are still weak, they command the attention as the fourth
influential power in the pharmaceutical market following the
10
original pharmaceutical companies, generic drug2 makers, and
foreign based pharmaceutical companies.
3.2 Characteristics of innovative R&D
(1) Capital intensive nature
R&D expenditure in pharmaceutical industry has been increasing
year by year. In 1991, the total cost has reached nearly 600 billion
yen. The proportion of R&D expenditure of total sales has
increased.drastically enough to create a burden for companies. (see
Figure 2)
11
2 A non-patented drug.
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Source: Management Coordination Agency, "Report on the Survey of Research
and Development"
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To recover this expense, it is necessary to produce high value
added and highly profitable pharmaceutical compounds and to
expand the market globally. In 1990, the percentage of R&D
expenditure of total sales in pharmaceutical industry(8.02%) is the
largest among all industries in Japan followed by communication
and electronics equipment industry(6.12%) and precision
Instrument industry(5.94%).3 The percentage of R&D expenditure
in Japan Pharmaceutical Manufactures Association(JPMA)4, which
consists of R&D oriented leading pharmaceutical manufacturers, is
higher(12.0% in 1990) than that of all drugs and medicines
industries in Japan.
The R&D of innovative drugs is time consuming and entails a higher
degree of risk and cost than that of proprietary drugs5. Generally
speaking, the development of one innovative chemical entities
requires the substantial investment of approximately 10 billion yen
to 20 billion yen, and 10 to 20 years to go through basic research,
pre-clinical trial, clinical trial.
(2) High risk
One British study(Halliday,Walker, and Lumley, op.cit. 1992) based
on data from the U.S., European, and Japanese companies, exhibits
3Japan Pharmaceutical Manufacturers Association, "Data Book 1992," pp. 48-
54
4Japan Pharmaceutical Manufactures Association(JPMA) was established in
1968. In 1990 JPMA member companies accounted for 87.6% of total industry
employees, 77.2% of total pharmaceutical production, 85.8% of ethical drug
production, 30.6% of OTC drug production.
5 Proprietary drugs are non-prescription, over-the-counter drugs.
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that the risk of failure in R&D is very high. Up to 9 out of 10 new
compounds entering clinical trials fail to reach the market. And on
average, only one in 3645 new compounds synthesized during the
past 20 years has become marketable. 6
In Japan, as a study of 17 companies' success rates of new drugs
from 1986 to 1992 exhibits, approximately 1 out of 2200 in-house
developments succeeded in obtaining government approval. During
6 years, 307570 compounds were investigated by 17 companies
and only 137 of them succeeded on the market.(see Figure 3)
6Redwood, Heinz, "Price Regulation and Pharmaceutical Research: The Limits
of Co-Existence," (Oldwicks Press) pp.2-3.
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Rate of Developing New Drug
(Results of the past five years[1986-1992]
companies)
No. of C.
Compou
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hemical
nd
Approved
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Application
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Pre-Clinical Studies Started
590
(1:520)
Synthesized or Extracted Compounds
307,570
(Source: Data Book 1993)
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with 17
in JapanFigure 3: Success
Globally, only ten companies have succeeded in marketing 14 so-
called 'blockbuster' 7 drugs from 1969 to 1988. (see Table 1)
Table 1:Year Of First Introduction Of 14 'Blockbuster'
Drugs
[ into any one of the world's 7 largest markets]
Each drug achieved global sales > $750m in 1990
Years Number Of Drugs
1969
1974
1975
1976
1979
1981
1984
1985
1987
1988
TOTAL
1
2
1
2
1
2
1
1
2
1
14
Source: Redwood's cross-analysis of Barclays de Zoete Wedd
Research and Pharmaprojects, 1991
(3) Correlation between innovation and globalization
Etienne Barral's study indicated that an "innovative" new drug8 has
strong relation to global market penetration. 69% of new drugs
7 A drug of which annual sales exceed $750 million is qualified as a
'blockbuster' drug.
8The term, "innovative" here, has narrower meaning than the definition in
this paper. Etienne Barral's definition restricts "an innovative drug" to a
radically therapeutically new drug.
*innovative drugs: therapeutically innovative drugs with new or known
chemical structure.
non-innovative drugs: therapeutically non-innovative drugs with new or
known chemical structure.
* globalized drugs(defined as being marketed in all 7 specified countries: the
USA, Japan, Germany, France, Italy, the United Kingdom, and Switzerland).
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which had appeared in the global market between 1975 to 1992
were innovative, whereas only 5% were non-innovative. (see Figure
4)
Figure 4: Innovation and Globalization
of 930 New Drugs 1975-1992
8%
21%
t /u/o
Source: Calculated from Barrel, 1992
As a result, he insisted that there is a strong correlation between
the innovative drugs and the global drugs. On the basis of this
result, Heinz Redwood conducted a Special Study for 'Major Global
Drugs" developed from 1970 to May 1992. His study indicates that
the U.S pharmaceutical industry demonstrated remarkable leads in
developing competitive innovative new drugs. The U.S. share
accounts for 43% of the total. (see Figure 5)
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- Innovative and Global
* Innovative but not
Global
* Neither Innovative
nor Global
Ol Global but not
Innovative
* internationalized drugs(defined as being available in 4 of 7 identified
countries including the Top-6 markets in the world)
* non-international drugs(sold in 3 or fewer of these countries)
Figure 5: Development of 265
'Major Global Drugs'
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The U.S. has been showing its cutting edge for twenty two years up
to now in developing innovative drugs and the leads cover the most
of therapeutic fields and are today remarkable especially in the
new fields of immunology and biotechnology where the U.S. has
70% share of 'Major Global Drug' and 58% share of compounds in
clinical development. (see Figure 6-1)
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Figure 6-1: Therapeutic Class Profiles by
National Origin
(265 Major Global Drugs Developed 1970 - May 1992)
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Japanese companies exhibit superior performance in developing
anti-infective drugs, followed by cardiovascular but the number of
global drugs is still small in other therapeutic areas. This event is
related to the size of the domestic market share where
cardiovascular account for the largest share, 18.1%, and antibiotics
the second largest, 12.3%, followed by central nervous system
agents, 9.4%. Antibiotics, though they had the largest share until
19
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1988, went down to second because of significant price cuts
throughout the 1980s. (see Figure 6-2)
Figure 6-2: Breakdown of Pharmaceuticals
by Main Therapeutic Categories
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Redwood indicated that the most recent period(1990- May, 1992)
shows that the Japanese share of 'Major Global Drug' has increased
rapidly to 21% next to the U.S.A. to 47%.
20
Cardiovascular
o- Anti-biotics
--* "C.N.S. agents
o - Gastrointestin
al agents
Other
metabolic
agents
Thus, innovative R&D tends to be relatively costly, risky, and time-
consuming, but once a company succeeds in marketing a innovative
new drug, it faces a high probability of expansion into world
markets. The disposition, high-risk, is one of the key factors to
allow medium and small sized companies to develop incremental
drugs, which could alleviate the risk somewhat owing to acquired
knowledge on procedures of development and testings, drug
reaction(ADR), etc.
3.3 Scope, significance, and trend of The Japanese
pharmaceutical industry
(1) Drug production
Japanese drug production in 1990 amounts 5,595.4 billion, or 1.3%
of GNP.9 The Japanese pharmaceutical industry is still relatively
small in sales size at global level. Takeda with the highest total
sales in Japan, ranked the 16th worldwide in 1990, with only half
of the sales volume of Merck & Co. The profit rate to total sales is
also smaller than that of the U.S. (see Figure 7)
9 Japan Pharmaceutical Manufactures Association, "Pharmaceutical Industry
in Japan 1992," p.1 .
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Figure 7: Financial Results of US Top 3
vs Japanese Top 3
Source: SCRIP Pharmaceutical Company League Tables 1991 $1=144.70
7000
6000
5000
4000
3000
2000
1000
0
( O3 = I
a.. C) W
e m--2
O ._0(, C
(,
25
20
15
10
E
Cn
5
0
22
E
(/3
::3
I I Sales of
Pharmaceutica
Is
"-- Profit(%)
European origin companies, however, tend to have equivalent or
smaller profit rate to total sales than Japanese companies ones. (see
Table 2)
Table 2: Profit
companies
rate to total sales of European origin
World rank
of sales
2
4
5
6
8
17
19
Company
Glaxo
Hoechst
Bayer
Ciba-Geigy
Sandoz
Rhone-Poulenc Rorer
ICI
Country
England
Germany
Germany
Switzerland
Switzerland
France
England
Profit rate
27.2%
3.8%
4.6%
5.1%
7.8%
0.0%
5.2%
Source: SCRIP Pharmaceutical Company League Tables 1991
In 1988, the concentration ratios of production value of 3, 5, 10
Japanese leading pharmaceutical companies, were 13.4%, 20.4%,
35.3%, respectively. 10 Those figures are smaller than those of
Japanese leading industries, such as electronics and automobiles.
Within pharmaceutical industry, medium or small sized companies
compete with each other. Thus, for smaller sized companies, the
large investment in innovative R&D can become a significant
burden and risk.
10 Fair Trade Commission, "Cumulative Concentration Ratio in Main
Industries."
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(2) Import and export
The total imports is about three times as much as exports. Total
imports amount to approximately $3.5b. (see Figure 8)
Figure 8: Pharmaceutical Trade in Japan
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Japan's ratio of pharmaceutical exports to total production is
significantly below that of other industrialized countries. However,
characteristics of exports has shifted as follows.
* In the past three decades, the pattern of pharmaceutical exports
has shifted its emphasis from non-patented bulk products to
patented products.
* The targeted countries for exports have shifted from other Asian
countries to Europe and the United States, although Asia remains
the most important market for finished products. l l
11 Reich, Michael R., "Why the Japanese Don't Export More Pharmaceuticals:
Health Policy As Industrial Policy," California Management Review Reprint
Series, 1990, p.12 6.
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* Exports
EJ Imports
* Trade Deficits
The Japanese pharmaceutical industry has grown up through
technology transfer or licensing of innovative new drugs from
foreign countries. Prior to 1984, technological imports had exceeded
exports.
In 1984, imports and exports came closer to being in balance and
the trend is still prevailing. This phenomenon indicates that the
Japanese technological value in pharmaceuticals has increased
enough to be exportable to global markets. (see Figure 9)
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Figure 9: Balance on Technological
Imports & Exports in the Japanese
Pharmaceutical Industry
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(3) New Chemical Entities(NCEs) 12
Japan has made significant progress in developing New Chemical
Entities(NCEs) over the last decade. In fact, the total number of
12 The generic name for a chemical that is being tested for marketed as a
potential drug. The compound can be at any stage in the development
process from discovery to initial marketing.
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Japanese NCEs introduced on the world market from 1981 to 1989
became the largest in the world. (see Figure 10)
Figure 10: Number of New Products Introduced
to the World by Country of Origin
1961-1980
4 a nI.
80 /
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Total Number of
1 J "/0
7%
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- USA U Japan U Germany E- Switzerland
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1981-1989
9%
18%
8%
Total Number of NCEs Introduced = 443
(Source: CMR News, December 1991)
In spite of these impressive figures, Etienne Barral's 1990 Study
exhibits that although Japan ranks among the seven highest nations
27
with respect to pharmaceutical R&D expenditure, the number of
innovative drugs13 with global marketing and therapeutic potential
is a below average. The one prominent characteristic of Japan,
France, and Italy, is that the proportion of non-global new drugs is
higher than that of the other countries. (the USA, Germany, the UK,
and Switzerland) 14
On the contrary, E.S. Hawkins, Michael Reich, et al. noted that recent
Japanese drugs are not merely imitations of foreign innovative
drugs.15 They analyzed the innovation of Japanese-originated
therapeutic drugs approved by the U.S. Food and Drug
Administration(FDA) from 1960 to 1989. They concluded the
following:
(i) During the 1980's, the number of approved drugs of Japanese
origin had increased by four times as much as the previous decade.
(ii) Approximately 30% out of 30 Japanese-originate drugs
approved by FDA during these 30 years have new chemical
structures and 10% incorporate both radically therapeutic and
structural innovation. Reportedly, only 20% of new drugs tend to
possess radically innovative characteristics in general. Considering
this fact, Japanese drugs can be recognized as presenting radically
innovative characters.
13see p.6. the Definition of Etienne Barral
14 Redwood, Heinz, "Price Regulation and Pharmaceutical Research: The
Limits of Co-Existence," (Oldwicks Press) pp.2-3.
15 Hawkins, E.S., Reich, M.R., et al., "Japanese-originated Pharmaceutical
Products in the U.S. 1960-1989: An Assessment of Innovation." CLIN
Pharmacol THER 1992.
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(iii) Japan has played an important role of developing U.S. best-
sellers drugs as well as discovering innovative NCEs.
(iv) A high degree of innovation contained in the chemical structure
is not necessarily correlated with therapeutic significance or market
success.
(v) Policy measures which encourage innovation need to be
carefully designed to have appropriate health consequences and to
be socially and politically acceptable.
The difference between two studies above largely depended on the
definition of "innovation." Barrel's definition made importance of
therapeutic innovation regardless of innovation on chemical
structures, while Reich's definition took into account of innovation
both in therapeutics and chemical structures.
Combining the theories of both Barral and Reich, one can conclude
that Japanese drugs tend to possess a high degree of innovation, not
in therapeutics but in chemical entity, and have yet to penetrate
world markets.
3.4 History of non-global new drugs
Why does the Japanese pharmaceutical industry tend to produce
non-global new drugs rather than global ones? Major factors
include the following.
29
(1) Large domestic market
The establishment of the National Health Insurance(NHI) in 1961
had raised drug consumption rapidly, especially ethical drugs 16.
This is mainly because this insurance covers most medical expenses
including prescribed drugs while a patient has to pay all cost of
OTC17 by oneself. As a result, the growth ratio of ethical drugs was
much bigger than that of OTC after the NHI was promulgated. Owing
to this insurance, the pharmaceutical market expanded rapidly
until the early 1980s, just before the sharp drug reimbursement
price cuts started. In 1991 the market, which is slightly smaller
than that of the United States, has become the second largest in the
world. 18 It totals approximately $33b. (see Figure 11-1, 11-2)
16 A drug available only through a prescription issued by a physician.
170ver-the-counter drugs. The drugs are non-prescription.
18Japan Pharmaceutical Manufactures Association, "Pharmaceutical
Industry in Japan 1992," p.1.
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in Japan
Source: Ministry of Health and Welfare, "Pharmaceutical Industry Survey"
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Thus, the Japanese pharmaceutical market was large enough for
domestic pharmaceutical companies to enjoy their benefits without
worrying about expanding their share of foreign markets.
This high pharmaceutical consumption results mainly from (i) so-
called 'price-gap', (ii) physicians' dispensing policy, (iii) high
insurance coverage, and (iv) Fee-for-service reimbursement policy.
Price-gap
The Ministry of Health and Welfare(MHW, or Koseisho) set the
prices for drugs based on Japan's National Health Insurance(NHI)
Price List under the Health Care Insurance System. Since the 1980s
the MHW has conducted the reduction of drug prices largely to
bring market prices of drugs in line with NHI Price List.
Pharmaceutical manufactures try to set market prices lower than
list prices to seek sales volumes. The 'price gap' between the
market price and NHI price brings profits to medical institutions
and medical doctors, so that they tend to prescribe medicines much
more than the other industrialized countries. This phenomenon is
remarkable, especially small sized hospitals and clinics where a
doctor tend to manage both financial and diagnostic functions. As
skill points(the fees for operation, treatment, and consultation) are
comparatively lower than material points(the fees for drugs and
diagnostic tests), profits from the 'price gap' will represent a
considerable amount of the revenue of medical institutions. A small
hospital, in which doctors have discretion to choose medicines,
manage the hospital, and do medical practices, tend to depend on
the revenue from the 'price gap.' Furthermore, the 'price gap'
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promotes purchasing high list price drugs which are able to have
wide discount range.
Physician dispensing policy
Traditionally, Japanese physicians have both prescribed and
dispensed drugs by themselves so that rate of prescription filled by
outside the hospitals is still low at present. As I mentioned above,
the "price gap" has contributed substantially to the income of
physicians and given a incentive to keep dispensing system inside
the hospitals. The more drugs physicians prescribe inside a medical
institution, the more profits from margin of drugs they can make.
High insurance coverage
The coverage of Japanese Health Care Insurance System is higher
than both the E.C. and the U.S.A. This insurance system mainly
consists of Insurance for Employees and National Health Insurance.
On average, 81%19 of patients' expenditure is covered under this
system.(see Figurel2)
1 9There are several types of health insurances which differ depending on
types of occupation and each of them has different proportion of coverage,
respectively.
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Figure 12: % Share of Total Pharmaceutical Expenditure by
Public Sector, 1990
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The same copayment rates apply to medical services and drugs.
Thanks to this high coverage, patients pay less attention to drug
prices and medical expenditure. This phenomenon was remarkable
in free medical care for the elderly introduced in 1973. After that,
as the medical and pharmaceutical expenditure of the elderly had
increased sharply, copayment for them resumed after 10 years
interval. the MHW is now considering the possibility of requiring
5% copayment by the elderly. Patients may ask for lower priced
drugs, but such a request would be very rare and difficult because
of the deference usually given to physicians.2 0
Fee-for-service reimbursement policy
Medical institutions can be reimbursed through the Medical Fee
Payment Fund depending on medical fee points based on the total
services. This system is called as "fee for service" or "benefit in
kind" system. Although medical fee points are assessed by the
Reviewing Auditing Committee, the prescriptions dispensed are
reimbursed with little change 21 . As a result, physicians can
dispense drugs as much as they want within "reasonable" extent
without considering their cost.
2 0 Ikegami, Naoki, Will, Mitchell, and Penner-Hahn, Joan, " Contributions of
Pharmaceutical prices, quantities, and innovation to aggregate
pharmaceutical expenditures in Japan," August,1993, p.4.
21Reich, Michael R., "Why the Japanese Don't Export More Pharmaceuticals:
Health Policy As Industrial Policy," California Management Review Reprint
Series, 1990, p.13 2 .
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These four factors have interacted and contributed to expanding
pharmaceutical consumption in Japan. As a result of this system,
both patients and physicians do not have to worry about drug
prices so much. Hence, Japanese domestic market has expanded
large enough to satisfy medium to small sized Japanese
pharmaceutical companies.
(2) Unique patent regulation
Prior to 1976, only process patents were applied to pharmaceutical
products. In other words, drugs containing identical compounds as a
new drug were regarded as distinct drugs if they were
manufactured using different methods. And the latter drugs had
the considerable possibility of eroding the former ones' market
because their tended to acquire a government approval in shorter
time as the efficacy had already been proved.
(3) Drug approval
Prior to 1967, Japan did not require domestic clinical trials on
safety or efficacy for approved foreign products. These products,
excluded from the definition of 'new drugs,' were able to gain rapid
approval in Japan. Consequently, The Japanese pharmaceutical
industry focused on seeking licences for the manufacture or
importing foreign medicines until the mid-1960s. A company which
succeeded in acquiring the licence of a prevailing drug abroad could
enjoy considerable benefit.
Also, Prior to the mid-1980s, foreign firms were prohibited from
applying for the first stage of approval of new drugs by themselves.
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The methods of distributing foreign pharmaceutical products in
Japan were either to establish a joint venture or to contract
licensing. As this regulation kept competitive foreign firms out of
Japanese market and protected Japanese pharmaceutical companies
from them, Japanese companies could enjoyed the large domestic
market. Most of Japanese pharmaceutical research laboratories
started with transferring foreign products to the domestic ones
which meet the domestic regulation. This traditional mind set has
been one of the obstacles preventing Japanese pharmaceutical
companies from producing innovative drugs.
Thus, protected by approval procedure and patent regulation, the
Japanese pharmaceutical firms extracted benefits from a significant
domestic market. Prior to 1984, as the figure 9 shows,
pharmaceutical technology had not been sophisticated enough to
obtain a trade surplus.
Though technological export of pharmaceutical industry exceeded
import after 1984, a significant trade deficit of pharmaceutical
products still exists. This fact indicates that Japanese
pharmaceutical firms, which were delayed to expand sales
networks abroad, tend to seek export technologies by a cross-
licensing or a technology transfer rather than export
pharmaceutical products themselves.
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4. Factors in the health care policies which influence
innovative R&D
There are a number of factors in health care policies which promote
or disturb innovative R&D. In this chapter, I will examine
1. the influence of each factor on R&D and
2. current obstacles in implementation of the policies.
4.1. Cost containment
The MHW is promoting a cost containment policy which inhibits the
expansion of medical expenditure resulting from aging society and
technological progress in medical practices. Does a cost containment
policy including containment of pharmaceutical expenditure
hamper the increase in total sales and profit of pharmaceutical
industry, therefore, hamper innovative R&D? I will explore this
question in this section. In order to prepare for a future aging
society, appropriate allocation of restricted public money is
inevitable for a sound health policy implementation, therefore, a
cost containment gives great impact on overall health care policies.
Cost containment policies which influences innovative R&D as
follows.
(1) Price regulation
The MHW sets the prices of drugs based on Japan's National Health
Insurance(NHI) Price List under the Health Care Insurance System.
Several pundits have suggested the strong relationship between
government price regulation and innovative R&D.
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Heinz Redwood conducted a research on the government price
regulation policy of the U.S.A, the E.C., and Japan. He concluded as
follows:
* The controlled price is not useful in inhibiting pharmaceutical
expenditure. Because of the regulation, there is no price competition
in the market, therefore no competition from generic drugs.
* The ethical drugs, of which prices are set at lower level to contain,
tend to last at the market and seek for sales volumes to expand
total sales. As a result, total pharmaceutical expenditure increases.
* Price regulation is apt to militate to reduce the standard of R&D
objectives to a 'play safe' level which meets to controlled prices, so
that the quality of pharmaceutical R&D would be deteriorated. So,
under price regulation, non-innovative new drugs for the domestic
market with 'contemporary' price tag will be more attractive and
penetrate the market. This phenomenon is apparent in Japan,
France, and Italy which have stringent price regulation. Although
they are the three of the world seventh highest pharmaceutical
R&D expenditure countries, the number of finding innovative new
drugs with global marketing and therapeutic potential is a below
average.
* On the contrary, in U.S., pricing freedom brings a strong incentive
toward R&D of innovative new drugs in therapeutic area which
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entail high risks. In pharmaceutical industry, the correlation exists
between pricing freedom and success in R&D of innovative drugs.2 2
As for Redwood's theory, a price regulation hamper the R&D for
innovative drugs. Is this theory applicable to Japan correctly?
Objectives of price regulation
First, Redwood's hypothesis that the Government set a price of a
drug lower to contain pharmaceutical expenditure is not necessarily
true. It is because a main objective of price regulation results from
'solidarity' conception. Medical treatments should be provided
equally to all citizens. Hence, NHI covers most of the medical
expenditure including pharmaceutical expenditure. Under a free
market, low income patients without insurance could not afford to
take expensive therapeutic medicines (e.g. patented medicines)
even if they would drastically improve the patients' conditions.
Such a 'solidarity' conception exists in the Japanese health care
policy, and so as to the price regulation. Therefore, price regulation
is not for containment of pharmaceutical expenditure, but for
equity in providing pharmaceuticals. Consequently, the MHW
theoretically can set the drug price higher along with 'solidarity
conception' as long as medical insurance can cover that cost.
Recently, the MHW has introduced the new price formula which
favors innovative drugs rather than generic drugs by putting
2 2Redwood, Heinz, "Price Regulation and Pharmaceutical Research: The
Limits of Co-Existence," (Oldwicks Press) pp.2-3.
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higher margin on the new drugs. Thus, the Government does not
necessarily set a price of a drug lower.
Higher ratio of pharmaceutical expenditure to health care
expenditure
Secondly, Redwood emphasizes that the controlled price is not
useful in inhibiting pharmaceutical expenditure. In Japan, the
proportion of pharmaceutical expenditures to health care
expenditures is unusually higher compared to the other
industrialized countries. (see Figurel3)
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1990 Japanese ratio of pharmaceutical expenditures to total health
care is still high. The figure is 17.3%, while 8.2% in the U.S.A.
Furthermore, the difference is more remarkable in public health
care: 19.6% in Japan vs 2.1% in U.S. However, in ten years Japanese
ratio of pharmaceutical expenditure to total and public health care
has been reduced by 4.8%, and 5.8%, respectively. This is mainly
because of annual or biennial reduction of pharmaceutical
reimbursement prices. (see Table 3) In a year when radical
reduction of reimbursement was conducted, growth rate of
pharmaceutical production was very small. In 1984, the production
growth was only 0.1% and the following year, only 0.6%, too.
Table 3: NHI Drug Price Reduction
Reduction
18.6%
N.A
4.9%
16.6%
6.0%
5.1%
N.A
10.2%
N.A
9.2%
N.A
8.1%
N.A
6.6%
Growth of pharmaceutical
oroduction
5.7%
8.2%
1.3%
0.1%
0.6%
7.0%
12.7%
4.9%
8.8%
1.7%
1.8%
N.A
N.A
N.A
(Source: MHW and Data Book 1992)
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Year
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
Although the proportion of pharmaceutical expenditures to health
care expenditures has been reduced by ongoing price reductions,
pharmaceutical expenditure is still high. The Japanese
pharmaceutical market represented 18.7% of the world market in
1990 following to the U.S.(27.4%). 23
Therefore, even with reduction in the ratio of pharmaceutical
expenditures to health care expenditures is reduced, it is still
unclear whether the containment of pharmaceutical expenditures
would succeed. However, some argue that a usage of
pharmaceuticals would replace the other medical
treatment(operation, injunction, etc.) with higher expenses and lead
to reduce total medical expenditure.
Listing of new drugs
Pharmaceutical production was hindered heavily by consecutive
price reduction. In 1986, however, the MHW introduced the
quarterly listing of new drugs on the NHI reimbursement price list.
The quarterly listing gave a big advantage to an innovative drug
manufactures because only within 3 months after a new drug
approved, it could be on the on the NHI reimbursement price list.
23Ikegami, Naoki, Will, Mitchell, and Penner-Hahn, Joan, " Contributions of
Pharmaceutical prices, quantities, and innovation to aggregate
pharmaceutical expenditures in Japan," August,1993, p.2.
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New pricing formula
Redwood hypothesizes that the government set new drug prices
lower. In fact, comparing U.S. and Japan top selling drug prices, the
U.S. prices are higher than Japanese. (see Table 4)
Table 4: 1989 the U.S. and Japanese Drug Prices
Brand name
Japan:
US:
Adalat
Procardia
Unit Common
(mg) dosage
(mg)
10 30
10 30-60
Price
(Y*)
Price
(Y**)
138 138
317-635 223-447
Captryl
Capoten
Herbessar
Cardizem
25 37.5-75 136-272 136-272
25 50-75 235-352 165-248
60 90 62 62
60 180-1200 441-662 311-621
Cimetidine
Raitidine
Hydrochloride
Cefaclor
Cefadoroxyl
Tagamet
Tagamet
Zantac
Zantac
Kefral
Ceclor
Camacef
Ultracef
200
200
150
150
250
250
250
250
800
800
300
300
750
750
750
1000-2000
264 264
627-941 441-662
286
725
419
1182
278
1172-2344
286
510
419
832
278
825-1650
Piroxicam
Sulindac
Feldene
Feldene
Clinoril
Clinoril
20 20
20 20
100
150
112
456
112
321
300 103 103
300-400 447-596 315-412
Mitomycin Mitomycin
Mutamycin
* PPP rate: I US dollar=196
** Exchange rate: I US dollar
Yen(rate used in original source)
= 138 Yen
Source: Japan Pharmaceutical Manufacturers Association (1991b)/
Ikegami, Naoki, Will, Mitchell, and Penner-Hahn, Joan, " Contributions of
Pharmaceutical prices, quantities, and innovation to aggregate
pharmaceutical expenditures in Japan," August,1993.
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Generic
name
Nifedipin
Captryl
Diltiazem
2
5
591
18195
591
12811
The Price difference is from 1.7 times to 30.8 times in PPP rate and
from 1.2 to 21.7 in exchange rate. Captryl, a antihypertensive drug,
has a small price difference. To the prices listed here, discounts
apply in both countries.
In 1991, Central Social Insurance Medical Council (Chuikyo), an
advisory organ for the MHW for.drug pricing, decided to raise the
mark up from 3% to 20% as a standard for innovative drugs to
stimulate innovative R&D. This new formula for an innovative drug
is applied to a radical one rather than incremental one, though the
boundary between two is ambiguous. Table 5 shows the difference
between former formula and current one.24 The pricing method
operates in the following manner.
(i) Chuikyo lists drugs with similar chemical structure, indications,
and pharmacological action as controls.
(ii) Chuikyo determines new drug prices on the basis of the control
list, comparing efficacy, safety, usefulness, economic value,
complementary addition etc.
(iii) Chuikyo determines new drug prices by the cost-based pricing
methods if there is no appropriate control drug.
24 Japan Pharmaceutical Manufactures Association, "Pharmaceutical
Industry in Japan 1992," p.1 9.
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Table 5: Outline of the NHI Drug Pricing Formula
for New Drugs
Basic philosophy
Details of markups
Projected increase
The former formula
Calculation shall be done
in comparison with the
NHI price of a drug
similar to the new drug
1. Markup for
pioneering
3% as a standard
(from 1.5% to 4.5%)
2. Markup for usefulness
3% as a standard
(from 1.5% to 4.5%)
3. Markup for market
potential
3% (fixed)
Markup for market
potential
A uniform 3% markup is
granted to drugs having
low NHI drug prices and
rather small total
markets
An increase of 1.5% to
10% over control drugs
used for comparison
The current formula
Same as the former
formula
1. Markup for
innovation2 5
20% as a standard
(from 10% to 30%)
2. Markup for
usefulness 26
3% as a standard
(from 1.5% to 4.5%)
3. Markup for market
potential
3% as a standard
(from 1.5% to 4.5%)
An increase of 1.5% to
30% over control drugs
for comparison
(Source: JPMA UPDATE, No.1, Dec. 1991)
When 10% to 30 % markup is determined for innovative drugs, a
company can profit to cover the initial investment in R&D.
25A markup for innovation is granted to drugs that satisfy all three of the
following criteria.
1. Represent a completely new concept.
2. Are clearly safer and more effective than existing drugs.
3. Make a noticeable contribution to the treatment of targeted diseases.
26A markup for usefulness is granted to drugs that satisfy any of the
following three criteria.
1. Are clearly more effective than existing drugs.
2. Are clearly safer than existing drugs.
3. Offer greater safety and effectiveness than existing products through
innovative formulation.
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Considering that the previous markup was from 1.5% to 4.5%, 20%
standard should promote a significant incentive for companies to
promote innovative R&D.
The first obstacle manifests itself through the implementation of a
new price formula. In 1994, the MHW announced the 6.6%
reduction of drug list prices as of April 1, 1994 on the basis of the
market price survey. This reduction includes a innovative anti-
cancer drug, interferon(IFN), and innovative cholesterol-reducing
drug Mevalotin and Lipobus whose sales surpassed expectations
when the prices were determined. The list prices of 5 items for
hepatitis C will be reduced by from 13.5% to 22.7% and Mevalotin
and Lipobus by 12.2%. The main reason for increased demand for
innovative drugs is allegedly that the number of targeted patients
has been increased than expected. 27 Another possible explanation
is high price for innovative drugs. Japanese health care system and
drug pricing system induce following tendencies:
* In Japan, drugs with higher NHI Price, which tend to be more
drastically discounted, apt to sell well because of the "price gap." As
mentioned above, physicians need pay less attention to drug prices
because of "fee for service" system. So do patients because of "high
insurance coverage." These three factors spur the consumption of
drugs, especially expensive one. In spite of main Japanese drug
prices 1/1.7 to 1/30.8 of U.S. prices, according to OECD, in 1989,
27
"Yomiuri Shinbun," March 10, 1994.
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Japanese per capita pharmaceutical expenditure amounted to
$189(PPP rate of 199 yen to $1), while $ 203 in the U.S. and
pharmaceutical market is second largest in the world.28
Thus, physicians are willing to use innovative drugs with from 10%
to 20% markup, when they find symptom of curable disease in
patients in spite of the seriousness of sickness.
*According to research on market share in the anti-infectives and
H2 blocker by Tanabe Seiyaku Co., Ltd., the more rapid diffusion of
new drugs in Japan can be observed.2 9 In Japan, newer drugs are
more expensive than older drugs in same kinds under any
circumstances. After a while, periodic cuts in the reimbursement
price of drugs, or "price revision 30", is conducted. As a result, the
economic incentive to prescribe new drugs increases in order to
reap the benefit of the "price gap."
* Apart from the "price gap", physicians are willing to prescribe a
new drug, which was admitted as safer and more effective than
existing drugs by the MHW's drug approval, to examine its safety
and efficacy by themselves. "Fee for service" system and "high
insurance coverage" encourage this feeling further.
28 lkegami, Naoki, Will, Mitchell, and Penner-Hahn, Joan, " Contributions of
Pharmaceutical prices, quantities, and innovation to aggregate
pharmaceutical expenditures in Japan," August,1993, p.2.
29 1kegami, Naoki, Will, Mitchell, and Penner-Hahn, Joan, Contributions of
Pharmaceutical prices, quantities, and innovation to aggregate
pharmaceutical expenditures in Japan," August, 1993, p.6 .
3 0Priced is revised by MHW according to the drug price survey.
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This "price revision" is conducted for the first time under the new
rule. A number of pharmaceutical companies including Sankyo, the
firm marketed Lipobus, reacted with fear that if this decision would
set a precedent for the future rule.
Chuikyo and representatives of pharmaceutical industry negotiated
the following terms.
* Chuikyo determined IFN prices by the cost-based pricing
methods. Chuikyo explained they would conduct this price revision
according to the change of "preconditions" by expanded market of
IFN. The representatives from pharmaceutical industry admitted
this assertion.
* On the contrary, the representatives insisted that precondition
did not change on the prices of Mevalotin and Lipobus determined
on the basis of the control list and opposed to the price reduction
only by the reason of their market expansion. Chuikyo pointed out
the necessity of price revision from the "balance of total drug price"
point of view.31
* The MHW explained the "market expansion" and the
"precondition".
3 1
"Nikkan Yakugyo(Daily Pharmaceutical Affairs)," vol 8795, Nov. 26, 1993.
p.1 0 .
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(i) There is no exact number accounting for market expansion but
they intend to establish a standard based on future experiences.
(ii) As quarterly sales reports are required for drugs whose prices
are determined by cost-based pricing, the MHW examines the
extent of market expansion along with this report.
(iii) A drug price determined by control list will be revised when its
precondition changed, therefore, the analogy of a compared drug
was undermined. The MHW examined the extent of market
expansion along with hearings from pharmaceutical companies or
press reports.
(iv) The MHW mentioned that they conduct price revision case by
case basis. There is no standard on timing nor period.3 2
The representatives from industry asserts to clarify the
interpretation of "precondition."33 Considering the tendency of
Japanese pharmaceutical market, the implementation of high
markup on innovative drugs entails a considerable obstacle to
promoting innovative R&D and cost containment together. To
overcome this, continuing revision of the "price gap" is required.
The MHW has been taking several countermeasures to the "price
gap", and those measures has contributed to reduce discrepancy
between NHI prices and market prices.
32
"Nikkan Yakugyo(Daily Pharmaceutical Affairs)," vol 8806, Dec. 10, 1993.
33
"Nikkan Yakugyo(Daily Pharmaceutical Affairs)," vol 8820, Jan. 5, 1994.
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(2) Price gap
The so-called "price gap" is said to contribute to distortion of both
demand and supply in the drug market.
In March, 1994, the MHW mentioned that the shrinking price
reduction rate proveed that the market prices have been coming
close to NHI List Prices. It emphasized that this year's reduction,
6.6%, indicated that the discrepancy became small.34 On the other
hand, physicians derive a profit from drugs, approximately 25.7% of
the total sum paid by insurance for drugs. This profit amounts to
6.7% of the total revenue for hospitals and 11.6% for clinics at
present35. Are these figures large or small? Providers argue that
these profits are justified because the hospitals and clinics need to
pay for the administrative costs associated with purchasing and
inventorying drugs. In addition, providers must make up for the
deficit arising from the low reimbursement allowed for services.36
We can attribute two incentives for innovative R&D to the "price
gap revision".
(i) The revision of the "price gap" promotes proper use of
innovative drugs not based on margin from the "price gap" but on
excellent efficacy and safety.
(ii) The revision of the "price gap" inhibits the overuse of drugs and
tends to reduce the growth rate of domestic pharmaceutical market
expansion. Therefore, the domestic pharmaceutical companies begin
34
"Yomiuri Shinbun," March 10, 1994.
35Kuno, M., "Kaitei Iryobokoku(Revised: National Ruin Due to Health Care),"
Doyukan, Tokyo, p.121, 1992.
36Ikegami, Naoki, Will, Mitchell, and Penner-Hahn, Joan, " Contributions of
Pharmaceutical prices, quantities, and innovation to aggregate
pharmaceutical expenditures in Japan," August,1993, p.3.
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to seek other markets abroad to make profits. They are obliged to
produce high-valued, innovative drugs to survive in world markets.
On the contrary, the revision of the "price gap" might hinder
innovative R&D because pharmaceutical expenditure is restrained,
therefore, the profit of companies might be decreased. Researchers
contended that policies designed to reduce profits could undermine
R&D efforts and thereby limit opportunity to develop NCEs with
potential social benefits.37 After 1986 when the profit rate of sales
grew from 4.7% to 6.0%, the rate moved constantly and any severe
reduction is not observed so far.
The Fair Trade Commission warned that the "price gap" distorted
the rational drug use and recommended that actions be taken to
rectify it. Some medical institutions and physicians opposed this
recommendation because:
* Medical fees related to drug expenditures usually does not
include the cost of providing wages and other services. Those kinds
of administrative fees are covered by the "price gap".
* Skill points are comparatively lower and should be reassessed to
meet current situation.
37 United States International Trade Commission, "Global Competitiveness of
U.S. Advanced Technology Manufacturing Industries: Pharmaceuticals,"
(USITC Publication, September 1991) p.2 -1 .
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To solve the "price gap" problem, the MHW has promoted the
following policies.
Improvement of distribution system
The number of wholesalers has decreased since 1983. Because of
biennial NHI Drug Price reduction, 'price gap' has been shrunken
and a discount has become difficult. As a result, Small wholesalers,
which did not have a strong sales network, were in trouble to
expand customers. (see Figure 14)
Figure4: The Number of Wholesalers
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Since April 1991, under the new invoice price system,
manufactures fix the invoice price to wholesalers, while before that,
manufactures determined the invoice price after the selling price to
medical institutions was determined, that is, manufactures could
control the rate of margin both to wholesalers and to themselves.
As a result, wholesalers margin became at most 2% and so that this
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low margin forced small wholesalers, which could not participate in
discount competition under severer sales condition, to merge into
large ones and streamline their management. (see Figure 15)
Figure 15:
Distribution Route of
Pharmaceuticals
[ Pharmaceutical
Wholesalers
/ Market Price
Medical Institutions
Hospitalsl Clinics
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(Source: Pharmaceutical Industry in Japan 1992)
"Weighted average method"
On April 1, 1992, the "weighted average" price replaced the "bulk-
line method3 8." When a discrepancy between the market price and
the NHI Drug Price is within the set target, the NHI Drug Price
38NHI drug price in Japan were long determined by the 90% and 81% bulk-
line methods. These were methods to set the revised NHI drug price - the
price corresponding to the 90th percentile or 81st percentile in the total
sales volume of a given drug whose markets prices were arranged in order of
price on an ascending scale.
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ManuFacuturers
would remain same, otherwise it would be reduced. (see Table 6)
Under the former bulk-line method, the MHW was not able to
investigate the actual market prices of individual drugs. The MHW
planed to reduce the percentage of the permissible allowance
biennially. There are three objectives in the "weighted average
method":
(i) to reflect market price more reasonably;
(ii) to future correct unnatural variation;
(iii) to further simplify the NHI price calculation method.
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Table 6: The New NHI Drug Pricing Formula
Listing method
Calculation method
Price increases for
drugs with low NHI
prices
Listing interval for
genetic drugs
NHI drug price survey
The former formula
Drugs are listed by
brand name
Prices are revised once
every two years
Bulk-line method
A 0.7% increase for the
1990 revision
- Reductions averaging
9.9% for 9,742 drugs
- Increases averaging
0.7% for 1,700 drugs
- No change for 1,910
drugs
- Overall revision rate: a
9.2% reduction
Listed once every two
years
All marketed forms of a
drug are covered in the
primary survey and
follow-up surveys
The current formula
Same as the former
method
Same as the former
method
Replace the bulk-line
method with a
permissible discrepancy
allowance method based
on the weighted average
price
Permissible allowance
1992 - 15%
1994 - 13%
1996 - 11%
1998 - 10%
The current NHI drug
price is calculated by
adding the percentage
shown above to its
weighted average price
Sufficient consideration
will be given to
increasing the prices of
drugs having low NHI
drug prices,
unprofitable drugs,
drugs listed in
Pharmacopoeia of Japan,
a and other drugs
required in treatment
Discussion to be held
regarding the annual
listing of such drugs
Same as the former
method
(Source: JPMA UPDATE No. 1, Dec 1991)
Separating dispensing from medical practice
As I mentioned in Chapter 2, coexistence of prescription and
dispensing of drugs enable physicians to earn margin form drugs.
Since 1989, the MHW has been promoting the separation of
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prescription and dispensing at 37 national hospitals.3 9 In 1990,
85.4% of the hospitals and 80.4% of the clinics dispensed
pharmaceuticals. 40At present, separation from medical practice is
reportedly enforced for about 12% of the number of prescriptions,
amounting to 145 million prescriptions. 41
Reimbursement for services
The MHW try to rise the reimbursement for services in exchange
for reducing the pharmaceutical reimbursement. In 1994, the
reimbursement for services was increased by 3.3 % while the
reimbursement for drugs was reduced by 6.6%. hSy carrying out
this, the MHW hope that the discrepancy between two
reimbursements will be decreased.
Thus, the Japanese price regulation does not necessarily follow
Redwood's theory, or "price regulation hampers the R&D for
innovative drugs." It is because:
* The government set comparatively higher price to an innovative
drug.(10-30% markup) Even the price may be lower than that of
U.S., overusage of drugs helps pharmaceutical industry to make
profit.
A drug with higher price sells well due to "fee-for-service,"
"price-gap," and "high insurance coverage."
39MHW, "Koseihakusho(White Paper 1989)," p.2 7 6.
4 0 MHW, 1992.
4 1Japan Pharmaceutical Manufactures Association, "Pharmaceutical
Industry in Japan 1992," p. 1 1.
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* An innovative drug can penetrate the market very quickly and
cannot stay longer because of periodical "price revision." As a
result, pharmaceutical firms cannot survive without marketing
innovative drugs continuously.
4.2. Drug approval regulation
A regulatory testing and approval process is also a key factor to
determine the strength innovative R&D. A company investigates
about 7,000 substances to create an efficient new chemical
compound, and conducts several animal tests on rats, mouse,
rodents, dogs, monkeys, etc., and clinical tests on humans to
maintain the safety and the efficacy of a new drug. In Japan, a
company spends approximately $150 million and 10 years to
develop one new drug4 2.
The approval procedure for new drugs is regulated under the
Pharmaceutical Affairs Law.(Law no.145 of August 10, 1960) A
company which intends to acquire an approval and licences for new
drugs has to prepare the information required by the Law through
clinical and pre-clinical trials. For products containing a new
chemical entity, the following results of testings are needed:
4 2 Kano,Yoshikazu, Takaishi, Yoshikazu, "Sentan-sangyo no Chitekishoyuken,
(The Intellectual Property Right of High-Technology,)" Toyo-
Keizaishinposha, July 1990, p. 130.
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(i) the outline of a drug and circumstances of the development - a
origin of the drug, a background of its discovery, and conditions of
use in foreign countries;
(ii) the characteristics of the drug and test methods- chemical
structures, physicochemical4 3 properties, standards and test
methods;
(iii) the safety - stability and endurance to strong light, high
temperature, high humidity, etc.;
(iv) the toxicity and teratogenicity - single and repeated dose
studies in various type of animals on reproduction, dependence,
antigenicity, mutagenicity, carcinogenicity, and local irritation;
(v) the pharmacology; actions in general and effects on target
organs;
(vi) the absorption, distribution, metabolism, and excretion; and
(vii) trial results conducted on humans.
Data From (i) to (vi) are provided through pre clinical trials and
(vii) provided through clinical trials.
Usually, a thick document submitted to the MHW requires
considerable amounts of time to prepare. Each test must be
conducted, as figure 16 shows.
4 3process pertaining to both physics and chemistry.
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Figure 16: Process of Approval
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of New Drugs
Pre-clinical trials should be conducted based on the Good
Laboratory Practice(GLP), a standard of testings for safety of a new
drug promulgated in 1983.
Clinical trials are divided into three phases. In phase I studies,
experiments on limited number of healthy volunteers are
conducted to confirm safety of new drugs. In phase II studies,
experiments on limited number of patients are conducted to
confirm safety and efficacy of new drugs. In phase III studies,
double blind trials on a large number of patients are conducted to
examine new drugs by comparing effects with those of control
drugs. Clinical trials should be conducted based on the Good Clinical
Practice(GCP), a standard of clinical testings' procedure promulgated
in 1990.
During the data preparation phase, companies apply to the local
prefectural government for a manufacturing / import approval and
licences. Then, the application is filed with the MHW.
the Pharmaceutical Affairs Bureau of the MHW, which oversees
drug regulation, consults with a New Drug Expert Committee of the
Central Pharmaceutical Affairs Council(CPAC), an advisory council to
the MHW for examination of new drugs. CPAC consists of authorities
in the medical, academic, and research fields who discuss questions
on therapeutic category, specifications, and analytical methods for
new drugs involved in application. After the examination, the
applicant is given an explanation of the Council's deliberation. The
Minister of Health and Welfare issued approval of new drugs on the
basis of the Councils report. From an application to an approval of a
new drug, 8 months for prescription drugs, 10 months for non-
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prescription drugs, and 6 months for in vitro44 diagnostics are
required in average, respectively.
Joseph A. DiMasi, et al. investigated on the number of acquired NCEs
for which INDs4 5 have been filed by U.S.-owned firms from source
in the U.S., the E.C., and Japan.46 (see Figurel7)
Figure 17: Number of acquired NCEs
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In 1960s, the number of NCEs acquired from Japanese source was
lowest among three countries. From the mid-1970, however, the
44Outside the living organism and in an artificial environment.
4 5 Investigation New Drug Application. An application that a drug sponsor
must submit to FDA before beginning tests of a new drug on humans.
46 DiMasi, Joseph A., Bryant, Natalie R., and Lasagna, Louis, "New drug
development in the United States from 1963 to 1990," Clinical Pharmacology &
Therapeutics, vol. 50, November 5, 1991. p.p. 478-479.
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number had increased rapidly and exceeded the United States. In
1981, it became parity to that of the E.C. As this research shows, the
recent MHW's drug approval regulation tends to provide more
approval to products of U.S.-owned firms than the FDA does.
A time consuming approval procedure undermines a new drug's
patent term and reduce its profit, while neglect of safety and
efficacy may expand risks of undesired adverse drug reaction(ADR)
which injures public health. Recently, the MHW has put priorities
on "promoting the R&D of the most medically demanded drugs" and
"maintaining transparency and proper procedures in a new drug
testing and approval procedure." To achieve this policy, the MHW
amended the Pharmaceutical Affairs Law and the revised first
clause to articulate "promoting public health by implementing
policies to prioritalize the R&D of the most medically demanded
drugs." 47 The details of their policies are as follows.
(1) Promote R&D to orphan drugs48
In October 1993, the Orphan Drug Act was enacted as a part of the
Pharmaceutical Affairs Law. R&D of orphan drugs takes more cost
and time because complicated pathological mechanisms of rare
diseases require wider ranging studies. Furthermore, less
marketability and profitability unable private companies to invest
47 From the speech of Motoyuki Fujii, a manager of the Pharmaceutical
Affairs Bureau of MHW, at ICH in Florida, U.S.A.
4 8Drugs for the treatment of rare diseases.
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their money to the R&D on such diseases. The legal requirements to
be recognized as orphan drugs are:
(i) an estimated patient number of less than 50,000 in Japan; and
(ii) a new drug with no adequate therapeutic substitute.
Once a candidate compound is legally designated as an orphan drug,
it can obtain several benefits:
(i) The MHW gives a priority review of application of orphan drugs.
Earlier and quicker examination encourage earlier marketability
and longer patent term residual which promote economic
advantage of orphan drugs;
(ii) The MHW provides research expense subsidies and tax
incentives to R&D of orphan drugs. This financial supports alleviate
financial burden of orphan drugs;
(iii) The MHW provides technological information support to these
drugs to help clarifying puzzled pathological mechanism;
(iv) After an orphan drug is marketed, the efficacy and safety of
the drug is re-examined for ten years instead of four or six years
for normal new drugs. In this re-examination period, the MHW does
not approve the drug which has equivalent therapeutics. This
system brings exclusive market of the drug without taking patent
right.
Selection for designation is conducted by CPAC on the basis of
criteria of the Pharmaceutical Affairs Bureau. Among more than
200 candidate drugs which have been examined for orphan drug
status from August to December in 1993, 40 pharmaceuticals were
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selected and began proceeding to be designated as legal orphan
drugs. 28 out of 40 selected were developed by non-Japanese
companies. 49
(2) Maintain the transparency of approval procedures
To maintain the transparency and objectivity of approval
procedures, the MHW discloses information on a new drug approval
through SBA. In SBA, scientific data in terms of quality, safety, and
efficacy and discovery through the new drug approval procedure
will be listed.
(3) International Conference on Harmonization(ICH)
History toward ICH
In January 1985, Market-Oriented, Sector-Selective(MOSS) Talks, an
intergovernmental negotiation to alleviate U.S.- Japan trade friction,
was held. The Talk mainly focused on such industries as
automobiles and electronics which brought significant trade deficits
to U.S.A., but the conference on pharmaceuticals and medical
devices was established in spite of large deficits of Japan. This was
because the U.S. government aimed at easier penetration to the
second largest pharmaceutical market in the world 50. As a result,
the following agreements reached:
(i) reduction of the evaluation period for new drug approval;
49From the speech of Ichikawa, Katsutaka, a counsellor for Pharmaceutical
Affairs, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, at
the New York Pharma Forum General Assembly.
5 0Yasuda, Yuzo, "Gekihensuru Iyakuhin Sangyo, (Drastically Changing
Pharmaceutical Industry)" Sannodaigaku Shuppan Bukan, March 10, 1993,
p.p. 22-54.
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(ii) improvement of requirements for approval(acceptance of
foreign data, improvement of registration transfer procedures, etc.);
(iii) regular, quarterly NHI drug price listing for new drugs;
(iv) provision of more opportunities to foreign and domestic
industry representatives to express their opinions on the
reimbursement policy.
Prior to the mid-1980s, foreign firms were prohibited from
applying for the first stage of approval of new drugs by themselves
in Japan. After this bilateral talk with the United States, the
regulation had been changed to allow foreign firms to access
Japanese market easily so that the Japanese pharmaceutical
market, which is the second largest in the world, became more
attractive to pharmaceutical companies abroad.s '
Purpose of ICH
Mutual recognition of regulatory requirement, such as inspections
and clinical trial data, has been talked and is currently underway
among the United States, the E.C. and Japan. The first session of "
the International Conference on Harmonization(ICH) of Technical
Requirements for Registration of Pharmaceuticals for Human Use"
was held in Brussels, Belgium, in November 1991, and the second
session in Florida, U.S.A. in October, 1993 to promote international
harmonization and rationalization in pharmaceutical regulatory
51 United States International Trade Commission, "Global Competitiveness of
U.S. Advanced Technology Manufacturing Industries: Pharmaceuticals,"
(USITC Publication, September 1991) p.3 -8 .
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affairs. The conference consists of Commission of the European
Communities(CEC), European Federation of Pharmaceutical
Industries Associations(EFPIA)52, the FDA, Pharmaceutical
Manufactures Association(PMA) 53, the MHW, the JPMA, and
International Federation of Pharmaceutical Manufacturers
Associations(IFPMA).
The main objective of ICH is to provide new drugs to patients and
doctors as soon as possible without compromising the quality,
safety, and efficacy of drugs. Missions of the United States, the E.C.
and Japan are to identify the exchangeable materials for drug
approval of each country, to unify key words and definition of
words, and to make a guideline for testings. As a result, testings
period will be shortened and the number of animals and patients
for testing will be decreased. Therefore, the reduction of the R&D
cost and the cost of approval procedure leads to supplement
financial resource to inevitable new drugs.
Mr. Stya, Chairman of PMA, President of Pfizer, pointed out that the
time and labor has been reduced by from 20 to 40 % and the
number of animals for testing by 27 % as a result of harmonization
of reproductive toxicity in the first session.54
Each subject is examined in terms of three aspects, quality, safety,
and efficacy by experts and pundits of each area.
5 2The federation of the national pharmaceutical industry associations in 16
European countries.
53 A U.S. trade organization for the U.S. pharmaceutical industry.
5 4
"Detailman," December, 1993, p. 42
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Quality area
Quality area includes stability testing, analytical validation,
impurities in new drugs substances, harmonization of
pharmacopoeial monographs and methods, and quality of
biotechnological products. This area mainly deal with scientific
subjects. For example, in stability testing, three countries set
common figures of temperature, testing period, amount of samples,
etc. and unify statistical methodology, technical terms, and
definition of words to establish the guideline and standard for
quality. Determination of scientific data is not so simple because of
uncertainty of their character. Whether a certain experiment is
inevitable or not, or why you choose 10mg instead of 11mg to a
certain test is a difficult question. As for biotechnological products,
three counties had already acknowledged the necessity of
international harmonization in ICH-1. However, biotechnology is
still its infancy. As the study on this field goes on, target industries
expand due to biotechnology's versatile ability applied to
pharmaceutical, chemical, environment, energy, agriculture, and
molecular electronics industries. In ICH-2, to examine the
harmonization concretely, three topics were chosen:
(i) manufacturing variations;
(ii) genetic stability;
(iii) stability of biotechnology products.
Reliability and validity of scientific data entail considerable
questions.
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Safety area
Safety area includes assessment of carcinogenic potential of
therapeutic agents, harmonization of genotoxicity testing
requirements, and harmonization of pre-clinical pharmacokinetics5 5
data.
In issues in assessment of carcinogenic potential of therapeutic
agents, " Guidance for dose selection for carcinogenicity studies of
therapeutics" was submitted as a consensus text for ICH-2. This
guideline insists that dose selection for carcinogenicity studies
should be on the basis of not maximum clinical dose but level of
exposure. In the process of dose selection, U.S.A. uses the methods
based on MTD, while the E.C. and Japan based on maximum clinical
dose and maximum feasible dose. Both methods seem to lack of
scientific grounds. Finally, the method considering the exposure
level which is based on the agreement of EGW was shown.
Three countries have already agreed with conducting
carcinogenicity studies of therapeutics on carcinogenic substances
and drugs more than 6-month clinical period. FDA asked for further
examination PMA insisted on unnecessity of carcinogenicity testings
on mice and rats which often show false-positive. The U.S. and
Japanese governments opposed it because of insufficient scientific
data which prove this phenomenon. Three countries agreed with
making a international protocol for a database by March, 1994,
then analyzing data on necessity of testings of rodents.
5 5The chemical kinetics(e.g. chemical reaction mechanisms) of
pharmaceuticals.
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Efficacy area
Efficacy area includes population exposure to assess clinical safety,
clinical data management, clinical study report, dose-response
information to support product registration, ethnic factors in the
acceptability of foreign data, good clinical practice, and studies in
support of special population.
If current guideline of population exposure to assess clinical safety
is accepted, population exposure requires 200 -300 cases and one
year while present Japanese regulation requires 50 - 100 cases and
6 months. As a results, the increase of the clinical testing cost will
be inevitable.
Some human clinical studies must be performed to domestic
patients. Foreign-based firms regard the incompatibility of clinical
tests as duplicate efforts. 56
As for acceptability of foreign data, some results of experiments
were shown in ICH-2. For example, Hajime Yasuhara, Professor of
Showa University pointed out that a variation is more remarkable
within a race than among races when he compared PK parameters
of 35 items to those of U.S. and the E.C. Moreover, after revised by
weight, the variation among races is diminished. On the contrary,
Kumagai from Daiichi Pharmaceutical Co. cited Captpril, a drug for
hypertension, as one remarkable example of dose difference:
37.5mg - 75mg/day in Japan, 50mg - 150mg/day in U.S.A., 12.5mg
56 United States International Trade Commission, "Global Competitiveness of
U.S. Advanced Technology Manufacturing Industries: Pharmaceuticals,"
(USITC Publication, September 1991) p.3 -1 1.
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- 150mg /day in the E.C.57 Three countries agreed to conducting
long range studies with medical and anthropological consideration.
The FDA mentioned that if ethnic differentiation in enzyme
metabolism is clarified in phase I of a clinical trial, the results is
applicable to phase 2 and 3 to revise data. If so, there is possibility
of establishing acceptable scientific guideline to three countries.
4.3 Intellectual Property Right(IPR)
R&D of innovative drugs is associated with large amount of time
and money to acquire the approval of governments. Innovative
pharmaceutical companies have to prepare a large volume of data
for both pre clinical and clinical tests, while "me too" companies can
eliminate enormous R&D cost through reverse-engineering or
information on compounds of new drugs opened to the public. Some
countries, especially developing countries, welcome "me too"
products on the basis of the idea that medical practice should be
provided to everyone equally.
In 1986, IPR "of data submitted for new drug approval regulation"
was negotiated in Uruguay round for trade liberalization under the
GATT(General Agreement on Tariffs and Trade). The
pharmaceutical industry of each industrialized country, which has
multinational and global characteristics requires harmonization of
IPR. As the World Intellectual Property Organization(WIPO) had not
been able to work effectively on intellectual property issues, the
table was shifted to Uruguay round and the IPC(Intellectual
57
"Detailman," December, 1993, p.6 3.
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Property Committee) from U.S.A., UNICE from the E.C., the
Federation of Economic Organizations(FEO, KEIDANREN) from Japan
decided to discuss this issues continuously as representatives of
each country. In Uruguay round, the U.S. asked for that "the data
submitted for new drug approval regulation" should be protected as
trade secrets. In 1988, three countries admitted that the data
should be protected as "proprietary information".
(1) Trade secret
The difference of Japanese drug approval procedure from that of
the U.S. makes protection of data by trade secret difficult. In Japan,
a company should open the data and materials of a new chemical
compound submitted for the drug approval to the public before
applying the approval. So, manufactures put the results of testings
of the new compound to general publication in order that the drug's
justification would be evaluated generally. This concept stems from
maintaining the authenticity of submitted data but it contradicts to
protecting secrets by trade secrets.58
(2) Re-examination period
After a new drug was marketed, the efficacy and safety is re-
examined in four or six years respectively depending on the
category of drugs. In this re-examination period, the MHW does not
approve the drug which has equivalent therapeutics, which might
58 Kano,Yoshikazu, Takaishi, Yoshikazu, "Sentan-sangyo no Chitekishoyuken,
(The Intellectual Property Right of High-Technology,)" Toyo-
Keizaishinposha, July 1990, pp. 127-155.
73
have same adverse drug reaction(ADR) as a original drug, before
the safety of the original one would be assured. It is because, from
the point of Pharmaceutical Affairs Law view, the MHW tries to
diminish the incidence of adverse drug reaction(ADR) from "me-
too" drugs59 as much as possible. If a drug does not satisfied with
expected efficacy and safety level, its approval is cancelled. Thus,
this concept is not from the point of view of the protection of IPR of
the drug but from the view of maintaining efficacy and safety or
preventing disastrous ADR.
(3) Patent Law
A patent law allows inventor to secure exclusive possession of his
invention for a certain period in exchange for making related
technology open to the public. The Japanese Patent Office(JPO)
conducts formal examination to applications. The term of Japanese
patents is 15 years from date of publication but no longer than 20
years after application. The average time from a Japanese patent
application to a registration is 5 years and 4 month, compared to
about 20 months in the United States. (see Figure 18)60 One of the
reasons for this is the significantly fewer examiners in the JPO.61
59 Defined broadly as a product that is therapeutically similar to an existing
drug. Some "me-too" are also has chemical similarity to the existing one.
6 0Ministry of Health and Welfare, "Nihon no Yakumu Gyosei,(Japanese
Pharmaceutical Affairs Administration), " p.149.
6 1United States International Trade Commission, "Global Competitiveness of
U.S. Advanced Technology Manufacturing Industries: Pharmaceuticals,"
(USITC Publication, September 1991) p.3-13.
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Compound patent
In 1976, the Japanese patent law was amended from providing
protection to only process patents to expanding to compound
patents. This practice results that foreign companies began to apply
patents in Japan. Without compound patents, imitators can produce
the innovative drugs invented by an innovative company through a
different process even if the inventor acquired some process
patents. Moreover, an inventor hardly can meet a burden of proof
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to process patent infringement, so that me-too companies can enjoy
earning profit by mimicking innovative drugs. Most developing
countries do not admit compound patents by the reason that
medical practice should be provided to everyone equally and of
being afraid that all compound patents seized by industrialized
countries. After 1976, the strengthen patent system gave Japanese
large companies impetus for increase R&D efforts.62
Patent term restoration
The Pharmaceutical Affairs Law prohibits to manufacture and
import drugs before a government approval for their safety and
efficacy to be acquired. As the approval usually requires
considerable time to go through examination and testing, a patent
term would expire or close to expire when manufacturing or
importing is approved. Therefore, the inventor cannot make use of
prerogative in the exclusivity of market given by a patent, even if
he succeeded in obtaining it. In October 1984, the Pharmaceutical
Policy Council emphasized the importance of the patent term
restoration to stimulate R&D activities. In 108th Diet Session, " The
Law for Amendments to the Patent Law etc." was passed and has
been enforced since January 1, 1988. Under the amendments, the
patent term is extended up to 5 years depending on the term in
which use of a patented invention is prevented by procedures for
approval under the Pharmaceutical Affairs Law. Japan is the second
62 United States International Trade Commission, "Global Competitiveness of
U.S. Advanced Technology Manufacturing Industries: Pharmaceuticals,"
(USITC Publication, September 1991) p.3-14. figure3-3
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fastest country which enacted patent term restoration legislation.63
The strengthened patent system attracts foreign firms as well.
Patent flooding
The claim allowed in Japanese patent applications tend to be
narrower than those in U.S. For instance, Japanese patent system
does not allow the doctrine of equivalent, i.e, that an accused device
may be found to infringe even if it does not precisely meet the
terms of a patent claim, if the patented can show that the accused
devise performs substantially the same function in substantially
the same way to achieve substantially the same result. This
narrowness opens the possibility that competitors obtain the
similar patents related to claimed invention by minor changes and
leads to "patent flooding." This practice can result in a patentee
being confined by competitors' patents and prevent the patentee
from enjoying his prerogative and compel him to enter into cross-
licences. An alternative method to avoid this harm is to apply for
several patents to obtain more complete coverage of the new
technology.64
4.4 Projects related to innovative R&D incentives
Preparing for further technological innovation in 21 century, some
government related activities are conducted to promote utilization
6 3Ministry of Health and Welfare, "Nihon no Yakumu Gyosei,(Japanese
Pharmaceutical Affairs Administration), " pp. 145-149.
64 United States International Trade Commission, "Global Competitiveness of
U.S. Advanced Technology Manufacturing Industries: Pharmaceuticals,"
(USITC Publication, September 1991) p.3 -1 3 .
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of emerging high technology especially in pharmaceutical and
medical area.
(1) The Japan Health Science Foundation
In April 1986, the Japan Health Science Foundation was established
to work for the promotion of drug development utilizing high
technology including biotechnology covering the pharmaceutical
industry and human science related industries. This foundation
cooperates with the MHW, other Government agencies, universities,
public research institutes, and private companies closely. The main
activities are described as follows.
General activities
* To promote R&D, the foundation supports Government-Private
Sector joint studies on communication of new technology,
estimation, and evaluation mainly in high technology fields.
* To set regulations and standards, the foundation monitors
industries opinion on applying techniques developed in such
advanced fields as biotechnology.
* To maintain research resources such as cells and genes, the
foundation investigates not only on Research Resource Banks(RRB)
but other institutions.
* The foundation sponsors open symposiums, study meeting
concerning basic research and advanced technology.
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* To promote information services, the foundation compile and
publish the foundation news and service reports and is studying on
a possible information reference system on research and
technological development by computer supports.
* The foundation is planning and investigating on middle and long
range projects and cross sectional projects over many organizations.
The Basic Health Research Projects(Joint Research
Activities)
In 1986, the MHW launched the Basic Science Research Project for
Longevity(renamed as the Basic Health Research Projects in 1988)
promote Government-Private sector joints study on human science
related area especially in biotechnology and new materials. This is
the first industry- involving projects sponsored by the MHW which
used to support only national universities and institutions. The
Japan Health Science Foundation was in charge of promoting this
project, which is started by strong requests from industries, in
order to make use of full ability and capacity of industries. In fiscal
year 1992, the MHW allocated 1,400 million to research activities
of this projects covering four fields. (see Table 7)
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Table 7: The Basic Health Research Projects
Field number of subjects
themes
Development of biotechnology as a 92 subjects under 23
basis of life science themes
Development of glycoengineering I subjects under 1
and its application to medical science themes
and health care
Study for evaluation, improvement 23 subjects under 6
and development technology for themes
medical materials forming the basis
of medical and welfare services
Clarification of biophylaxis as a basic 34 subjects under 6
mechanism of health maintenance themes
Source: Ministry of Health and Welfare, "Nihon no Yakumu
Pharmaceutical Affairs Administration)."
and budget
(mil.¥)
1,360
460
330
410
Gyosei,(Japanese
Project for development of anti-AIDS and related products
Industries, universities, and government cooperate with each other
to develop drugs for AIDS. This project consists of the following
activities: R&D of drugs for AIDS; development of therapeutic drugs
for AIDS-associated symptoms and of prophylatic drugs for AIDS,
and establishment of evaluation methods for the drugs; research on
basic technology for development of drugs for AIDS; development
of fractionated plasma preparation by recombinant DNA technology;
and research for development of AIDS vaccines.
Overall research projects for new drug development
Industries, universities, and government collaborate with each
other in consolidation of a research ground for a development of
epoch-making drugs. The government encourages international
joint studies, imputation of foreign scientists, and dispatch of
Japanese workers to overseas.
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(2) The Foundation for Adverse Drug Reaction Relief
The Foundation for Adverse Drug Reaction Relief was established in
1979 to rescue suffers of ADR including patients with AIDS caused
by blood preparation. The Fund provides suffers to medical expense
and disability annuity mainly from contribution by pharmaceutical
and related manufacturers and government subsidies. The expense
for relief has been increased annually and 1988 expense reached
three times as much as that of 1984. More than 60% of applications
is accepted. The number of application tend to increase as the
system becomes famous among related companies. (see Figure 19)
Figure 19: ADR Relief
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(3) Research promotion system for drugs, medical devices,
etc., by high technology
The MHW established an investment and financing system for
private companies engaging in R&D activities for drugs, medical
devises, etc., especially in biotechnology, new materials, and
electronics fields. The MHW submitted to the Ordinary Session of
the 108th Diet a "Bill Concerning Partial Amendments to the Law
Concerning the Foundation for Adverse Drug Reaction Relief" to
promote this activity. The Diet passed the bill in May 1987 and was
enforced in October 1987. The Foundation for Adverse Drug
Reaction Relief was renamed as Drug Fund for Adverse Reaction
Relief and Research Promotion and a new function, providing
financial support to drugs, medical devices, etc., in advanced
technology field, was added.
Private companies, which conduct R&D of manufacturing or selling
methods for drugs, medical devices, quasi-drugs, and cosmetics can,
apply for the Fund to obtain financing support. The Fund decides
after examination of submitted contents of projects. Main services
of the Fund are as follows:
Investment service
The Fund invests mainly to a joint project by two or more
enterprises engaged in the R&D arising at the stage of basic study,
which promises great improvements in the industrial technology
standards for the medical field or which renovates industrial
technology by linking expertise in different segments of industry.
The Fund provides the greater part of funds required for
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establishing a juridical person by two or more companies for
technical development research(up to 70% of the total investment
for seven years).
Financing services
The Fund loans mainly to the R&D arising at the stage of applied
research, which promises to solve a great medical problem in the
country. The Fund provides a necessary amount of money during
the study for about five years in which the interest rate is kept on
a fixed level. Results of the study will be evaluated on its
termination, and the interest rate level will be determined within
the limit of interest rates on long-term loans used by the Trust
Fund Bureau(currently 6.7%). The funded company repay within 10
years after completion of the study, but it is exempted from
interest payment in case of failure.
Other supporting services
Besides the investment and financing services, the Fund supports
private enterprises by managing joint research projects with
national institutes, offer services for commissioned research by
companies, invites researchers from abroad, and collects, supplies
and investigates high-tech information.
5. Conclusion
From the discussion above, I concluded that the Japanese health
care policies provide strong incentives for innovative R&D.
Although a part of the policies encourage radical innovation rather
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than incremental one, there is no negative effect on incremental
drugs. It is generic drugs that would suffer a considerable loss.
These health care policies can be divided in four categories: direct
incentives for innovative R&D; globalization and harmonization;
faster approval of drugs with safety and efficacy; and cost
containment
(1) Direct incentives to innovative R&D
To enhance innovative R&D, the Government gives incentives
through several policies. The following policies belong to this
category: New price formula; quarterly listing of new drugs; orphan
drug act; Government projects and research promotion.
New price formula
The MHW gives the incentive to produce an innovative drug
especially radical one through high mark-up of new price
formula(10-30% mark-up). Some health policy measures and
circumstances amplify this formula's influence on innovative R&D.
The factors are as follows:
A drug with higher price sells well due to "high insurance
coverage," "fee-for-service," "price-gap," and "physicians'
willingness."
* Because of "high insurance coverage(81% in average)",
patients tend to be less price conscious to medical fee.
* Because of "fee-for-service", physicians tend to be less price
conscious to medical expenditure.
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* Because of "price gap", physicians tend to buy drugs with
high price tag which tend to be more drastically discounted.
*Physicians' willingness to prescribe new drugs, which were
admitted as safer and more effective than existing drugs by
the MHW contribute to overusage of innovative drugs.
These four factors contribute to overusage of drugs especially
expensive drugs.
* Generally, even the Japanese drug prices may be lower(1/1.7 to
1/30.8) compared to U.S. drugs, overusage of drugs helps
pharmaceutical industry to make profits.
(per capita pharmaceutical expenditure: Japan $189, U.S. $ 203)
* An innovative drug can penetrate the market very quickly but its
life-cycle is very short because periodical "price revision" would
reduce its price depending on its sales volume. Hence,
pharmaceutical firms cannot survive without marketing innovative
drugs on an ongoing basis.
On the other hand, there are some obstacles and uncertainties in
implementing this new formula. In order to promote a stable
innovative R&D, the MHW should implement following
countermeasures:
A while after an innovative drug is marketed, the price revision
will be conducted according to the change of "preconditions" by
"market expansion". It is necessary to clarify the conditions,
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standards, and measures of "price revision" and clarify the key
words, "market expansion" and "precondition".
* Set a clear definition of "innovative new drugs" in the new price
formula.
Quarterly listing of new drugs
The quarterly listing of new drugs on the NHI reimbursement price
list in 1986 gave a big advantage to an innovative drug
manufactures because only within 3 months after a new drug
approved, it could be on the on the NHI reimbursement price list.
The Orphan Drug Act
The MHW revised first clause of the Pharmaceutical Affairs Law to
articulate "promoting public health by implementing the policy to
prioritalize the R&D of the most medically demanded drugs".
Orphan drugs, which have less marketability and profitability, were
categorized to this definition. R&D of orphan drugs tend to be
innovative because of complicated pathological mechanism of
diseases. Once a candidate compound is legally designated as an
orphan drug, it can obtain several benefits and priorities:
A priority review to orphan drugs which encourages earlier
marketability and longer residual patent term and gives economic
advantage;
* Research expense subsidies and tax incentives to R&D of orphan
drugs;
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* Technological information support to clarify puzzled pathological
mechanism;
* Ten years re-examination period, which brings exclusive market
of the drug without taking patent right because the MHW does not
approve the drug which has equivalent therapeutics.
More than half of selected drugs were non-Japanese origin. It
indicates that in this field, globalization and harmonization of
approval procedure have been proceeded as well.
Government projects and research promotion
There are a number of projects aiming at enhancing innovative
R&D. However, the total amount of fund is still small.
* the MHW, which used to support only national universities and
institutions, allocated 1,400 million for the first time to Basic
Health Research Projects in the Japan Health Science Foundation,
which involved industries. The Foundation promotes drug
development utilizing high technology such as biotechnology and
new materials covering the pharmaceutical industry and human
science related industries, anti-AIDS and related projects, and a
development of epoch-making drugs.
* The MHW established an investment and financing system for
private companies engaging in R&D activities for drugs, medical
devises, etc., especially in biotechnology, new materials, and
electronics fields to encourage innovative R&D through economic
incentives. The Fund invests mainly to a joint project of basic R&D
as investment services, while loans mainly to the applied R&D
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which promises to solve a great medical problem in the country as
financing services.
(2) Globalization and harmonization
The Government promotes globalization and harmonization of
polices through intergovernmental negotiation, which is sometimes
attained by pressure from foreign government mainly aiming at
opening the Japanese market. Globalization and harmonization
enhance competitiveness of world markets. Moreover, the products
with competitiveness can survive in open market. This policy
compels pharmaceutical companies to do innovative R&D in order to
survive a stringent competition. The following policies belong to
this category: Patent term restoration; compound patent; the ICH;
transparent drug approval procedure.
Patent term restoration and compound patent
The Japanese Government policy is welcoming strong patent and
harmonizing IPR through GATT. Correlation between patent rights
and innovative R&D is not clear because patent right encourage
public disclosure of technical information and competitors can get
the knowledge very quickly. However, both 1976 Compound patent
and 1984 patent term restoration gave a big advantage to
innovative companies by reducing competitors' opportunity to
penetrate the market.
Obstacles to promoting strong patents are as follows:
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* In Uruguay round, the U.S. asked for that "the data submitted for
new drug approval regulation" should be protected as trade secrets.
However, the difference of Japanese drug approval procedure from
that of the U.S. makes protection of data by trade secret difficult. In
Japan, a company should open the data and materials of a new
chemical compound submitted for the drug approval to the public
before applying the approval. Hence, manufactures put the results
of testings of the new compound to general publication in order
that the drug's justification would be evaluated generally.
* The average time from a Japanese patent application to a
registration is still long(5.3 years) compared with the United
States(20 months), so it should be reduced. One of the reasons for
this is the significantly fewer examiners in the Japan Patent Office.
* Most developing countries would not like to admit compound
patents by the reason that medical practices should be provided to
everyone equally and of being afraid that all compound patents
seized by industrialized countries.
* The claim allowed in Japanese patent applications tend to be
narrower. This narrowness opens the possibility that competitors
obtain the similar patents related to claimed invention by minor
changes and leads to "patent flooding." This practice can result in a
patentee being confined by competitors' patents and prevent the
patentee from enjoying his prerogative and compel him to enter
into cross-licences. An alternative method to avoid this harm is to
apply for several patents to obtain more complete coverage of the
new technology.
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The ICH
ICH is aiming at set up the "world guideline" for drug application.
For instance, in area of reproductive toxicity, the
guideline,"Detection of Toxicity to Reproduction for Medical
Products," has already been completed. On the other hand, necessity
of certain carcinogenicity studies on second species, which often
show false-positive, has not yet been determined because of
insufficient scientific data. "How safe is safe?" is a difficult question.
In a number of areas,
technological constraints exist. The government should take
continuous initiative to:
* implement determined guidelines of ICH;
* accumulate scientific data by prospective studies especially in the
areas without sufficient data;
* coordinate scientific data in the world;
*take early and flexible actions to biotechnology, which may
contain unforeseeable results, before the actions become too late.
Transparent drug approval procedure
Without explicit targets to be approved as a new drug, both foreign
and domestic pharmaceutical industries would lose the impetus to
development of new drugs.
To maintain the transparency and objectivity of approval
procedures, the MHW discloses information on a new drug approval
through SBA. In SBA, scientific data in terms of quality, safety, and
efficacy and discovery through the new drug approval procedure
will be listed.
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(3) Faster approval of drugs with safety and efficacy
A time consuming approval procedure undermines a new drug's
patent term and reduce its profit, while neglect of safety and
efficacy may expand risks of undesired adverse drug reaction(ADR)
which
undermine stable demand of drugs. The following policies belong to
this category: the ICH, RDA relief.
The ICH
Through ICH, pharmaceutical industries in the U.S., Japan, the E.C.
tries to attain faster approval with safety and efficacy. The
conference focused on the following points.
·Eliminating redundancy of tests in order to attain faster
approval(ex. unifying the pre-clinical and clinical tests)
* Setting standards and guideline of each test to make
exchangeable data, or documents
* To obtain common recognition how safe is safe, experts exchange
their opinions.
ADR relief
ADR brings a big financial damage as well as deterioration of
confidence of a company. New drugs, as they have no precedent,
tend to be vulnerable to ADR. The Foundation for Adverse Drug
Reaction Relief was established in 1979 to rescue suffers of ADR
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including patients with AIDS. The expense for relief has been
increased annually and 1988 expense reached three times as much
as that of 1984.
(4) Cost containment
The Government tries to contain the increasing medical expenditure
owing to ageing society, the structural change of diseases, and
emerging new technology. So far, there is no strong symptom that
cost containment policy gives negative impact on innovative R&D.
Because the government policies prioritalize new drugs and
innovative drugs rather than generic drugs and old drugs. The
following policies belong to this category: revision of the "price gap."
Revision of the "price gap"
The "price gap" supers consumption of drugs with high margin
excessively. We can expect two incentives the revision of the "price
gap" brings to innovative R&D.
*The revision of "price gap" promotes proper use of innovative
drugs not based on margin from "price gap" but on excellent
efficacy and safety.
* The revision of "price gap" inhibits overuse of drugs and tends to
reduce the growth rate of a domestic pharmaceutical market
expansion, therefore, the domestic pharmaceutical companies begin
to seek another market abroad to make profits. They are obliged to
produce high-valued, innovative drugs to survive in world markets.
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In spite of several countermeasures to the "price gap" taken by the
MHW including consecutive "price cut", improvement of distribution
system, "weighted average method", separating dispensing from
medical practice, rectifying reimbursement for services, the "price
gap" still exists.(The profits from price gap: 6.7% of the total
revenue for hospitals, 11.6% for clinics) Consequently, rectifying
"price gap" should be done continuously, though there are some
resistances from physicians, pharmaceutical companies, and
wholesalers.
As described above, a number of the Japanese policies is promoting
innovative R&D explicitly. Furthermore, increasing demand and
availability of innovative drugs by epidemiologic change, emerging
new type of diseases, and emerging new technologies, provide
positive effects on innovative R&D. On the other hand, these health
care policies would bring substantial damage to "me-too"
companies. In order to survive in the pharmaceutical industry in
coming era, "me-too" companies will be forced to seek merger,
specialization of products, promotion of innovative R&D, conversion
of company's policy, etc. Even to the Japanese leading
manufacturers, further efforts would be required to carry out
innovative R&D successfully considering their weakness in
marketing on world markets, dependency on incremental drugs in
parts, weakness in developing therapeutically innovative drugs, etc.
Some of health care policies to innovative R&D has begun very
recently. A considerable time lag exists before effects of health care
policies to innovative R&D ,which entail considering time-
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consuming testings and drug approval procedure, appears.
Considering the current innovation oriented health policies, I can
expect that innovative drugs would emerge on the Japanese market
next 10 years from now.
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